Microsomal metabolism of triazenylimidazoles
- PMID: 241485
Microsomal metabolism of triazenylimidazoles
Abstract
The antitumor agents 5-(3,3-dimethyl-1-triazenyl)imidazole-4-carboxamide (DIC) and 5-[3,3-bis(2-chloroethyl)-1-triazenyl]imidazole-4-carboxamide (BIC) are substrates for NADPH-requiring microsomal enzymes of mouse liver. The products of DIC oxidation are 5-aminoimidazole-4-carboxamide (AIC) and formaldehyde. Those for BIC are AIC and, presumably, 2-chloroacetaldehyde. For DIC, the reaction has a pH optimum of 9.0; and the Michaelis constant (Km) is 0.25 mM. At lower pH values, the Km is not greatly increased; but there is a sharp rise in the Km values above pH 9.0. For the enzyme-catalyzed production of AIC from BIC, the pH optimum is 7.5; the Km value for BIC is 0.47 mM. Of a variety of tissues tested for enzymatic activity, only liver accomplishes the conversion of DIC and BIC to AIC. Most of the activity in the liver is located in the microsomal fraction, although detectable activity is present in washed mitochondria. For liver microsomes, the rate of reaction for BIC is greater than that for DIC, but apparently neither rate is fast enough to allow extensive metabolism of large doses of these agents.
Similar articles
-
Microsomal metabolism of nitrosoureas.Cancer Res. 1975 Feb;35(2):296-301. Cancer Res. 1975. PMID: 234031
-
Cellular and biochemical aspects of growth retardation in rat fetuses induced by maternal administration of selected anticancer agents.Teratology. 1975 Dec;12(3):259-70. doi: 10.1002/tera.1420120307. Teratology. 1975. PMID: 1198332
-
Metabolism of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in human and animal tumor tissue.Cancer Chemother Rep. 1972 Aug;56(4):465-72. Cancer Chemother Rep. 1972. PMID: 5081589 No abstract available.
-
The metabolism of triazene antitumor drugs.Pharmacol Ther. 1987;32(2):191-205. doi: 10.1016/0163-7258(87)90059-3. Pharmacol Ther. 1987. PMID: 3299401 Review. No abstract available.
-
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.Eur J Cancer (1965). 1972 Feb;8(1):85-92. doi: 10.1016/0014-2964(72)90087-4. Eur J Cancer (1965). 1972. PMID: 4552317 Review. No abstract available.
Cited by
-
Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.Cancer Chemother Pharmacol. 1982;9(2):103-9. doi: 10.1007/BF00265388. Cancer Chemother Pharmacol. 1982. PMID: 7172404
-
Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity.Int J Mol Sci. 2025 Jan 24;26(3):988. doi: 10.3390/ijms26030988. Int J Mol Sci. 2025. PMID: 39940757 Free PMC article. Review.
-
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.Br J Cancer. 2009 Jan 27;100(2):322-33. doi: 10.1038/sj.bjc.6604856. Epub 2009 Jan 6. Br J Cancer. 2009. PMID: 19127257 Free PMC article.
-
N-methyl antitumour agents. A distinct class of anticancer drugs?Cancer Chemother Pharmacol. 1987;19(2):91-102. doi: 10.1007/BF00254559. Cancer Chemother Pharmacol. 1987. PMID: 3552281 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous